United Therapeutics EVP exercises options, sells shares
UNITED THERAPEUTICS Corp EVP & General Counsel Paul A. Mahon exercised stock options and sold the resulting shares in a pre-planned transaction.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp EVP & General Counsel Paul A. Mahon exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share and received 8,300 shares.
On the same date, he sold 8,300 shares of common stock in multiple open-market trades at weighted average prices generally around the mid-$560s per share, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After these transactions, he directly owns 45,172 shares of UNITED THERAPEUTICS common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,300 shares ($3.48M approx. pre-tax spread)
Exercise and Sale
13 txns
Insider
MAHON PAUL A
Role
EVP & GENERAL COUNSEL
Sold
8,300 shs ($4.70M)
Approx. gross sale proceeds
$4.70M
Approx. exercise cost
$1.21M
Approx. pre-tax spread
$3.48M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 8,300 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,300 | $146.03 | $1.21M |
| Sale | Common Stock | 514 | $560.2959 | $288K |
| Sale | Common Stock | 351 | $561.6876 | $197K |
| Sale | Common Stock | 774 | $562.3436 | $435K |
| Sale | Common Stock | 371 | $563.5762 | $209K |
| Sale | Common Stock | 1,115 | $564.5528 | $629K |
| Sale | Common Stock | 543 | $565.6577 | $307K |
| Sale | Common Stock | 1,629 | $566.664 | $923K |
| Sale | Common Stock | 1,403 | $567.5461 | $796K |
| Sale | Common Stock | 690 | $568.7949 | $392K |
| Sale | Common Stock | 710 | $569.6113 | $404K |
| Sale | Common Stock | 200 | $571.606 | $114K |
Holdings After Transaction:
Stock Option — 16,900 contracts (Direct);
Common Stock — 45,172 shares (Direct)
Footnotes (12)
- F1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $568.17 to $569.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $569.485 to $569.775. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $571.53 to $571.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $559.83 to $560.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $560.885 to $561.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $562.00 to $562.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $563.03 to $564.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $564.09 to $565.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $565.09 to $566.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $566.12 to $567.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $567.17 to $568.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 8,300 shares
Exercise price: $146.03/share
Shares sold: 8,300 shares
+2 more
5 metrics
Options exercised
8,300 shares
Stock options exercised into common stock on April 2, 2026
Exercise price
$146.03/share
Exercise price of stock options converted on April 2, 2026
Shares sold
8,300 shares
Total common shares sold in open-market transactions on April 2, 2026
Sale price range
$559.83–$571.72
Price ranges for multiple trades as disclosed in Form 4 footnotes
Shares owned after
45,172 shares
Direct UNITED THERAPEUTICS common stock holdings after the reported transactions
Key Terms
Rule 10b5-1, stock options, weighted average price
3 terms
Rule 10b5-1 financial
"pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
stock options financial
"This is an exercise of stock options and sale of the resulting shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did UTHR executive Paul A. Mahon report in this Form 4?
Paul A. Mahon, EVP & General Counsel of UNITED THERAPEUTICS (UTHR), reported exercising stock options for 8,300 shares at $146.03 per share and selling 8,300 common shares in open-market transactions. These trades were made under a pre-arranged Rule 10b5-1 plan.
How many UNITED THERAPEUTICS (UTHR) options did Paul A. Mahon exercise?
He exercised stock options covering 8,300 shares of UNITED THERAPEUTICS common stock at an exercise price of $146.03 per share. The options had an original exercise date of March 15, 2020 and an expiration date of March 15, 2027, as reflected in the filing.
Was Paul A. Mahon’s UTHR trading done under a Rule 10b5-1 plan?
Yes. A footnote explains the option exercise and resulting share sales were executed under a pre-arranged Rule 10b5-1 trading plan entered into by Paul A. Mahon on August 11, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily.
What is the significance of the weighted average price disclosures in the UTHR Form 4?
Several sales were executed in multiple trades, so the Form 4 discloses a weighted average price for each group. Footnotes clarify specific price ranges for these trades and state that full trade details will be provided to the SEC, the issuer or shareholders upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
